Biotechnology Jobs

• Stevenage
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of medical directors and clinical scientists designing and executing early-phase oncology trials, including first-in-human, dose-escalation and proof-of-concept studies, while bridging preclinical discovery and clinical development. Accountable for clinical development plans, benefit-risk, regulatory submissions and translational biomarker strategy across lung and head/neck cancer assets.

AI/ML

• Zug, Switzerland
• Hybrid · 2 days in office
• US$284,250 – US$473,750 pa
• Director · manages people

Leads a team of early clinical development medical directors and clinical scientists, owning Phase I/II clinical development plans including first-in-human, dose-escalation and proof-of-concept studies in lung and head/neck cancers. Bridges preclinical discovery and clinical development, driving translational and biomarker strategy with cross-functional and regulatory partners.

AI/ML

• Durham Blackwell Street
• Hybrid
• US$188,100 – US$313,500 pa
• Director

Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.

NONMEM · R

• Stevenage
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining predictive biomarkers, patient segmentation and go/no-go decision criteria. Represents Translational Medicine on Clinical Matrix Teams and works across diagnostics, data sciences and external partners to validate assays and deliver biomarker data packages.

NGS · FISH · PCR +5

• Grimsby
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Oversees biomarker assay development, sample testing plans and data packages across platforms such as NGS, IHC, flow cytometry and ctDNA, working with internal and external partners.

IHC/IF · Liquid Biopsy · ctDNA +3

• Waltham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with cross-functional partners in digital medicine, translational imaging and systems modelling. Based in the newly established Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• London
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, imaging, modelling and data science partners. Reports into the Respiratory, Immunology & Inflammation Research Unit.

AI/ML · Digital Medicine · Translational Imaging +3

• Stevenage
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and works with digital medicine, translational imaging and modelling specialists. Based in Stevenage with a planned relocation to Cambridge, UK by early 2029.

MIDD · QSP · AI/ML

• Durham, United States
• Hybrid
• US$222,750 – US$371,250 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Coordinates CPMS activities across assets, approves study designs and regulatory documents, and partners with digital medicine, translational imaging, biostatistics and AI/ML teams. Reports into the Respiratory, Immunology & Inflammation Research Unit within the new Clinical Pharmacology and Quantitative Medicine organisation.

MIDD · QSP · AI/ML

• Waltham, United States
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions, and partners with digital medicine, translational imaging, modelling and data science teams to embed quantitative approaches into asset-level decisions.

MIDD · QSP · AI/ML

• London
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Sits in the Clinical Pharmacology and Quantitative Medicine organisation, partnering with digital medicine, translational imaging, modelling and data science teams, and drafting regulatory content for FDA, EMA and ICH submissions.

MIDD · QSP · AI/ML

• Stevenage
• US$188,100 – US$313,500 pa
• Director

Lead end-to-end application of Model-Informed Drug Development across the drug development lifecycle, from first-in-human studies through filing and lifecycle management, providing clinical pharmacology strategy and evidence generation. Draft and review regulatory content for FDA, EMA, CDE, PMDA and ICH, and build cross-functional partnerships across digital medicine, translational imaging, AI/ML and biostatistics. The role sits in the newly established Clinical Pharmacology and Quantitative Medicine organisation, reporting into the Respiratory, Immunology & Inflammation Research Unit.

MIDD · QSP · AI/ML

• Durham, United States
• US$188,100 – US$313,500 pa
• Director

Leads end-to-end application of Model-Informed Drug Development and clinical pharmacology strategy across the drug development lifecycle, from first-in-human studies through filing and lifecycle management. Partners with digital medicine, translational imaging, modelling and biostatistics teams, and drafts regulatory content for FDA, EMA, CDE, PMDA and ICH submissions. Based in the newly formed Clinical Pharmacology and Quantitative Medicine organisation, with a strong publication and scientific leadership remit.

MIDD · QSP · AI/ML

• Baar Onyx
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, FISH, PCR, IHC/IF, flow cytometry, liquid biopsy/ctDNA and multi-omic analyses, and oversees sample testing plans and biomarker data packages for clinical and regulatory decisions.

NGS · FISH · PCR +6

• USA - Pennsylvania - Upper Providence
• Hybrid
• US$189,750 – US$316,250 pa
• Director

Leads the design and execution of clinical biomarker and translational medicine strategies for late-stage oncology assets, defining patient segmentation and decision criteria within Clinical Matrix Teams. Validates predictive, pharmacodynamic and resistance biomarkers using platforms such as NGS, ctDNA, flow cytometry and multi-omic analyses to inform dose selection and go/no-go decisions.

IHC/IF · Liquid Biopsy · ctDNA +3